Remove Medical Remove Pharmaceutical Remove Treatments
article thumbnail

Pelage Pharmaceuticals Announces $16.75M Series A Financing to Advance Hair Loss Treatment

The Dermatology Digest

Pelage Pharmaceuticals has closed a $16.75 million Series A financing led by GV with participation from Main Street Advisors, Visionary Ventures and YK BioVentures to advance a first-in-class treatment for androgenetic alopecia and other types of alopecia including chemotherapy-induced hair loss.

article thumbnail

Ligand Pharmaceuticals Launches Pelthos to Accelerate Commercialization of Zelsuvmi for Molluscum; Appoints New CEO

The Dermatology Digest

Ligand Pharmaceuticals is launching Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and has appointed Scott Plesha as Chief Executive Officer to accelerate the commercialization of berdazimer topical gel, 10.3% (Zelsuvmi) for the treatment of molluscum contagiosum. Watch Now: Nanette B. in September 2023.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Weighing Risks Vs. Benefits of Systemic AD Treatments

The Dermatology Digest

Shared-decision making focused on weighing risks versus benefits is key when choosing the most appropriate systemic atopic dermatitis (AD) treatment for a patient, according to new research presented at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Washington, DC. some of the JAK inhibitors).

article thumbnail

LEVEL UP Period 2 Data: AD Patients Who Switched From Dupilumab to Upadacitinib Hit Higher Treatment Targets

The Dermatology Digest

Atopic dermatitis (AD) patients who switched to upadacitinib (Rinvoq, AbbVie) from dupilumab (Dupixent, Regeneron, and Sanofi) hit higher treatment targets, according to results from Period 2 of the LEVEL UP study. Both groups had similar proportions of patients with treatment-emergent adverse events (TEAEs).

article thumbnail

Sneak Peek Inside the CSU Treatment Pipeline

The Dermatology Digest

Lio, MD, a Clinical Assistant Professor of Dermatology and Pediatrics at Northwestern University Feinberg School of Medicine and a partner at Medical Dermatology Associates of Chicago, discusses which ones works best. Just because they are little doesn’t mean we should be afraid to treat them and make their skin disease better,” she stresses.

article thumbnail

News You Can Use: Verrica Receives Permanent J-Code for YCANTH 

The Dermatology Digest

The Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-Code (J7354) for Verrica’s YCANTH, a molluscum contagiosum treatment. Medicaid and Medicare patient populations,” says Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals, in a news release. “In

article thumbnail

There Are So Many Skincare Lines– Is One Better Than Another?

Renee Rouleau

Pharmaceutical and Medical Advancements Ingredients that have been traditionally used for non-skincare purposes are now finding their way into the beauty industry. Even Botox, popular in the modern day for smoothing fine lines and plumping the skin, was first used as a treatment for Parkinson’s.

Skincare 195